Full text is available at the source.
Comparative outcomes of adding SGLT2 inhibitors versus incretin-based therapies to insulin in type 2 diabetes
Comparing the effects of adding SGLT2 inhibitors or incretin-based treatments to insulin in type 2 diabetes
AI simplified
Abstract
SGLT2 inhibitor use was associated with significantly lower risks of major microvascular complications compared to both DPP-4 inhibitors and GLP-1 receptor agonists.
- SGLT2 inhibitors reduced the risk of major microvascular complications by 63% compared to DPP-4 inhibitors.
- SGLT2 inhibitors also decreased the risk of major microvascular complications by 43% compared to GLP-1 receptor agonists.
- Compared to DPP-4 inhibitors, SGLT2 inhibitors were linked to a 43% lower risk of major adverse cardiovascular events.
- A 58% lower risk of all-cause mortality was associated with SGLT2 inhibitor use compared to DPP-4 inhibitors.
AI simplified